Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2024
Between 2017 and 2024, nine CAR-T products reached commercialization and this number is continuing to climb. Of these, six are U.S. FDA-approved CAR-T cell therapies, each of which has received approvals in other major healthcare markets as well. The six U.S. FDA approved products include: - Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (ciltacabtagene autoleucel)
In addition, two CAR-T therapies have received approval from the Chinese National Medical Products Administration, Relma-cel and Yuanruida, and one CAR-T cell therapy has received approval from the Indian Central Drugs Standard Control Organisation, NexCAR19.
Currently, all of the nine marketed CAR-T cell therapy products and nearly three-quarters (75%) of the ongoing clinical trials utilize an autologous treatment approach. Thus, the next frontier for CAR-T cell therapies will be the development of allogeneic CAR-T cell therapies. Solid tumor applications also attracting unprecedented investment.
This billion dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are now proliferating in all major healthcare markets worldwide.
For the next 48 hours only, you can claim it for $840 Off (20% Off):
To claim your discount, enter the code "CART20" into the Coupon Box during checking.
With the competitive nature of this market, you don’t have the time to do the research. Claim this report to become immediately informed about global market dynamics, without missing critical opportunities.
Remember to act fast, because this offer expires this Monday, September 9th, at midnight.
|
